Led · Grant · Jul 2023

Idoven offers an AI cardiology-as-a-service platform that augments cardiologists' and non-cardiology clinicians' ability to identify, triage, and diagnose patients at scale. Led by cardiologist and CEO Manuel Marina Breysse, its technology evolved from a desktop software created in Madrid in 2018 to a cloud-based AI solution used by medical device manufacturers and pharmaceutical companies. The company shifted from a closed platform to an open one that can integrate with third-party hardware, software, electronic medical record systems, and pharma companies' digital solutions. Idoven counts partners including AstraZeneca, Abbott, GE Healthcare, FIFPRO, Google, Santander, and the Real Madrid Foundation. It intends to use the new funding to accelerate rollout of new solutions, support healthcare professionals in accurately and efficiently diagnosing cardiovascular disease, and further its geographic expansion. The articles disclose the raise but do not specify financial metrics or the round size. Idoven builds AI-driven tools that work with standard electrocardiographs, including a cloud platform called Willem, to detect and prognosticate cardiovascular disease and develop disease biomarkers. The company’s technology is used for patient identification, risk stratification, prognosis and monitoring cardiovascular safety of drugs. Idoven is leading the ASSIST innovation consortium to create an AI-based solution for early diagnosis and accurate triage of acute myocardial infarction. As part of ASSIST, the company aims to integrate its platform into clinical workflows to reduce time to diagnosis and optimize communication between clinical teams. Idoven projects significant clinical and economic impact from ASSIST, targeting faster diagnoses and broader adoption across healthcare systems. The company is supported by EIT Health funding for the two-year ASSIST project to advance validation and deployment of its tools. Idoven develops Willem, an AI-powered platform that improves the speed, consistency and accuracy of electrocardiogram (ECG) interpretation and prediction. Its proprietary algorithms work with existing ECG devices and are being applied to develop disease biomarkers for patient identification, risk stratification, prognosis and drug cardiac safety monitoring. The solution is cloud-based, hardware-agnostic, and available via API, able to analyse ECGs of any duration and from any device — from 1-lead smartwatch ECGs to 12-lead hospital and long-duration ambulatory recordings. Led by CEO Dr. Marina Manuel Breysse, the company trains its models on a broad database of signals to enhance detection of arrhythmias and cardiac abnormalities. Idoven plans to use the new funding to further develop its AI platform and accelerate hiring to advance early diagnosis and precision medicine for cardiovascular diseases.

Participated · Grant · Nov 2022

Exheus develops an RNA‑based diagnostic platform that analyzes expression of all genes in the blood transcriptome to detect health anomalies and produce personalized clinical recommendations. The company positions its test as the most advanced commercial RNA analysis technology in the world and has launched initial products to validate biomarkers and assess market fit. Exheus was founded in mid‑2020 as a spin‑off of Hospital Sant Pau – IIB Sant Pau and UPC and was incubated at The Collider (Mobile World Capital Barcelona). Future plans include international expansion into European health systems, building a commercial structure to access those systems, completing regulatory requirements for cross‑border operation, and digitizing the product into a B2B automated interactive platform for clinicians. On the financial side, Exheus has previously raised more than €500k in 2021 and continues to secure non‑dilutive and equity financing to fund growth.

Led · Equity · Nov 2019

TeiaCare develops a proprietary platform, Ancelia, that uses optical sensors and artificial intelligence to monitor residential care environments and convert data into actionable insights for care staff. The company targets nursing homes, rehabilitation centres, and dementia care units and currently serves more than 150 clients across over 200 facilities, covering about 75,000 residents. Founded in 2018 by Guido Magrin and Luca Iozzia, TeiaCare is expanding its product scope toward broader healthcare and home care settings. With the new funding, it plans to scale its business model, enhance its Data, Spatial, and Care Intelligence capabilities, and begin international expansion focused initially on France and Spain.